Investors interested in Medical - Drugs stocks are likely familiar with Assertio (ASRT) and IPSEN SA ADR (IPSEY). But which of these two stocks offers value investors a better bang for their buck ...

Assertio is downgraded to 'Sell' due to deteriorating fundamentals and limited growth prospects. Rolvedon now comprises ~58% of revenue but faces competitive pressures and limited TAM, constraining ...

The shares of commercial pharmaceutical company Assertio Therapeutics (ASRT) have slumped more than 40% in price year-to-date. But the stock gained momentum after the company reported ...

Assertio Holdings (ASRT) has achieved significant product and service advancements and increased its market reach over the past few months. Furthermore, it has solid fundamentals and is currently ...

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail ...

Assertio Holdings (ASRT) is scheduled to report earnings on March 10, 2025. The last reported earnings were for reported on November 11, 2024 for Q3.

Investors with an interest in Medical - Drugs stocks have likely encountered both Assertio (ASRT) and Pacira (PCRX). But which of these two stocks is more attractive to value investors? We'll need to ...